Slide 1: Roche
Slide 2: Forward-looking statements
This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, str
Slide 3: Roche HY 2026 results
Roche HY 2026 results Basel, 23 July 2026
Slide 4: Group
Group Thomas Schinecker Chief Executive Officer
Slide 5: Performance, Portfolio progress, Outlook
Performance Portfolio progress Outlook
Slide 6: HY 2026: COP growth at +10% ahead of sales growth at +6%
HY 2026: COP growth at +10% ahead of sales growth at +6%* HY results all at CER ▪ Group sales growth +6%, Pharma +6% and Diagnostics +3% (still impacted by the healthcare pricing reforms in China) ▪ Strong bottom line performance with Core OP +10% and Core OP margin +1.7%p; Core EPS +9% ▪ LOE impact
Slide 7: HY 2026: Strong Pharma sales driving Group growth
HY 2026: Strong Pharma sales driving Group growth Sales impacted by low flu season and Diagnostics healthcare pricing reforms in China HY 2026 HY 2025 Change in % CHFbn CHFbn CHF CER Pharmaceuticals Division 23.6 24.0 -1 6 Diagnostics Division 6.7 7.0 -3 3 Roche Group 30.4 30.9 -2 ##### 6 CER: Const
Slide 8: HY 2026: Consistent strong growth
HY 2026: Consistent strong growth Sales impacted by low flu season and Diagnostics healthcare pricing reforms in China Group sales growth %CER +15% +10% +9% +9% +9% +9% +8% +8% +6% +6% +6% +5% +5% +2% +1% +2% +1% 0% COVID-19 pandemic Pandemic phase out Post-pandemic Base business: +1%* Base business
Slide 9: Key growth drivers of the Roche portfolio
Key growth drivers of the Roche portfolio Growth driven by a broad and diversified portfolio 2026 sales Diagnostics: Pathology Lab with strong +3% (CHFbn, YoY CER growth) growth; Core Lab growing despite China Phesgo: Conversion ongoing; HER2+ BC franchise healthcare pricing reforms to peak in 2026
Slide 10: Performance, Portfolio progress, Outlook
Performance Portfolio progress Outlook
Slide 11: Pharma: Continuous pipeline progress through partnering and M&A
Pharma: Continuous pipeline progress through partnering and M&A Addition of a BTK degrader with BIC potential through Nurix deal to strengthen oncology and beyond Onc/Heme, Ophthalmology Onc/Heme Onc/Heme Immunology CVRM CVRM CVRM CVRM Immuno & Neuro BTK Anti-TL1A siRNA CDKi Dual GLP- Long-acting Wn
Slide 12: Pharma: Up to 19 NMEs with launch potential by 2030
Pharma: Up to 19 NMEs with launch potential by 2030 Positive Ph III (KRASCENDO 1) divarasib in 2L+ KRAS G12C+ NSCLC; upcoming sefaxersen readout in IgAN afimkibart 0.5-1bn peak sales 1-2bn peak sales enicepatide** IBD, Atopic derm, RA, MASH >3bn peak sales Obesity +/- T2D 2-3bn peak sales sefaxersen
Slide 13: Diagnostics: Key Business Development across Customer Areas
Diagnostics: Key Business Development across Customer Areas PathAI acquisition* to expand pathology portfolio; recent deals to strengthen oncology ecosystem * Molecular Lab Molecular Lab Molecular Lab Molecular Lab Molecular Lab Pathology Lab Near Patient Care Sequencing-by- Ultra-rapid PCR Syndromi
Slide 14: Diagnostics: Key technology launches driving future growth
Diagnostics: Key technology launches driving future growth AXELIOS 1 sequencing solution launched in June 2026 Key platform launches Selected assays cobas Lp(a) Gen 2 Near Patient Care Core Lab Molecular Lab Cardiovascular risk Elecsys hs-TnT Gen 6 Acute coronary syndrome Accu-Chek SmartGuide cobas
Slide 15: Performance, Portfolio progress, Outlook
Performance Portfolio progress Outlook
Slide 16: 2026 guidance confirmed
2026 guidance confirmed LOE impact of roughly CHF 0.6bn expected for 2026 Group sales growth1 Mid single digit sales growth Core EPS growth1 High single digit Core EPS growth Dividend outlook Further increase dividend in Swiss francs 1. At CER: Constant exchange rates (avg. full year 2025); LOE: Los
Slide 17: Finance
Finance Alan Hippe Chief Financial Officer
Slide 18: Results, Cash & balance sheet, Currency guidance & outlook
Results Cash & balance sheet Currency guidance & outlook
Slide 19: HY 2026: Group performance
HY 2026: Group performance Sales increase of +6% and Core EPS increase of +9% at CER 2026 2025 Change in % CHFm CHFm CHF CER Sales 30,364 30,944 -2 +6 Core operating profit 11,856 12,010 -1 +10 as % of sales 39.0 38.8 Core net income 9,216 9,319 -1 +11 as % of sales 30.4 30.1 Core EPS (in CHF) 10.85
Slide 20: HY 2026: Group sales growth +6%
HY 2026: Group sales growth +6% Business growth exceeding impact of healthcare pricing reforms in China and LOE +6% at CER CHFm +359 +1,697 -244 -131 -2,261 30,944 30,364 HY 2025 Pharma LOE Dia China Fx HY 2026 (excl. LOE) (excl. China) healthcare pricing reforms Totals may include differences due t
Slide 21: HY 2026: Group core operating profit
HY 2026: Group core operating profit Core operating profit up +10%, driven by higher sales and effective cost management 2026 2026 vs. 2025 CHFm Abs. CERm CER growth Sales 30,364 +1,681 6% Other revenue 1,088 +258 29% Cost of sales -7,673 -391 5% R&D -5,765 -66 1% SG&A -6,370 -221 3% OOI&E 212 -87 -
Slide 22: HY 2026: Core operating profit and margin
HY 2026: Core operating profit and margin 52.2% 53.0% % of sales +2.0%p¹ 38.8% 39.0% +1.7%p¹ 18.0% 17.5% +10%¹ CHFm +10%¹ +0.6%p¹ 12,522 12,532 12,010 11,856 +6%¹ 2025 2026 1,250 1,180 Roche Group Pharma Division Diagnostics Division Note: Group core operating profit includes -1.9bn from Corporate (
Slide 23: HY 2026: Core net financial result
HY 2026: Core net financial result Improvement mainly driven by higher gains on equity securities CHFm ▪ Net financial result improved by +42m / -7% at CER ▪ Interest expenses1 stable at CER -729 -687 +43 -82 +96 -15 HY 2025 Equity Net interest Interest Other HY 2026 securities income expenses1 1. I
Slide 24: HY 2026: Core tax rate
HY 2026: Core tax rate Tax rate stable compared to HY 2025 17.4% +0.1% 17.5% Effective tax rate Effective tax rate HY 2025 HY 2026 All at reported exchange rates 24
Slide 25: HY 2026: Core EPS
HY 2026: Core EPS Increase in operations partially offset by lower gains on product disposals +9.3% 11.71 -1.0%p +0.4%p -0.3%p -2.1%p +12.3%p 10.72 HY 2025 Operations1 Product disposals Financial Effective tax All other effects HY 2026 & disposal of income/expense rate change subsidiaries All at CER
Slide 26: HY 2026: Non-core and IFRS income
HY 2026: Non-core and IFRS income Non-core items up vs. PY mainly due to higher impairment of intangible assets 2026 2025 Var. at Change in % CHFm CHFm CERm CHF CER Core operating profit 11,856 12,010 +1,173 -1 +10 Global restructuring plans -765 -1,023 +222 Amortisation of intangible assets -391 -3
Slide 27: Results, Cash & balance sheet, Currency guidance & outlook
Results Cash & balance sheet Currency guidance & outlook
Slide 28: HY 2026: Group operating free cash flow
HY 2026: Group operating free cash flow OFCF up by +21% mainly driven by higher cash operating profit, partly offset by NWC movement CHFm -434 +25 +144 +1,446 -625 6,889 OFCF up by +21% (+1,180m at CER) 6,264 5,708 HY 2025 OP, net of cash NWC Investments Investments HY 2026 Foreign HY 2026 (CER) adj
Slide 29: HY 2026: Operating free cash flow and margin
HY 2026: Operating free cash flow and margin % of sales 47.7% 49.2% 35.6% 35.7% 35.5% +1.9%p¹ 34.4% 19.8% 20.6% +1.6%p¹ +1.9%p¹ +2.7%p¹ +13%¹ -3.3% 0.2% +11%¹ 16.8% 14.4% CHFm +13%¹ 8,533 23,440 8,428 +4.8%p¹ 21,833 22,014 -1.1%p¹ 20,823 +21%¹ 6,114 6,264 -¹ 2025 2026 14 -4%¹ 2024 2025 2,402 -232 1,
Slide 30: HY 2026: Group net debt development
HY 2026: Group net debt development Net debt higher by CHF -5.9bn vs. YE 2025 Free cash flow CHF +4.2 CHFbn Dividends paid -8.3 -16.2 Trans. own eq. inst. -0.6 M&A & all. trans. -0.4 -2.1 Curr. transl. & oth. -0.8 -22.1 +6.3 Taxes -1.6 Treasury -0.5 -10.1 Net debt Operating Non-operating Dividends,
Slide 31: Balance sheet 30 June 2026
Balance sheet 30 June 2026 Equity ratio at 37% (31 Dec 2025: 38%; 30 Jun 2025: 35%) % change in CER % change in CER CHFbn vs. 31 Dec 2025 vs. 31 Dec 2025 Cash and 100.7 -3% 100.7 -3% 98.2 98.2 marketable 15.5 9.7 -36% securities 15% 10% Current 28.0 28.8 +2% Other liabilities 28% 25.7 29% current 23
Slide 32: Results, Cash & balance sheet, Currency guidance & outlook
Results Cash & balance sheet Currency guidance & outlook
Slide 33: Expected 2026 currency impact
Expected 2026 currency impact USD / CHF Assumed avg. YTD 2026 -13% -9% -6% -4% 0.90 Assuming the 30 June 2026 exchange rates remain stable 0.86 0.84 0.83 until the end of 2026. 0.78 0.79 2026 impact1 is expected to be (%p): 0.79 0.80 Q1 Q2 Q3 Q4 0.79 0.77 0.79 0.79 0.78 0.80 0.81 0.81 0.81 0.81 0.81
Slide 34: 2026 guidance confirmed
2026 guidance confirmed LOE impact of roughly CHF 0.6bn expected for 2026 Group sales growth1 Mid single digit sales growth Core EPS growth1 High single digit Core EPS growth Dividend outlook Further increase dividend in Swiss francs 1. At CER: Constant exchange rates (avg. full year 2025); LOE: Los
Slide 35: Pharmaceuticals Division
Pharmaceuticals Division Teresa Graham CEO Roche Pharmaceuticals
Slide 36: HY 2026: Pharmaceuticals sales
HY 2026: Pharmaceuticals sales All regions delivering growth HY 2026 HY 2025 Change in % CHFm CHFm CHF CER Pharmaceuticals Division 23,629 23,985 -1 6 United States 12,229 12,670 -3 6 Europe 4,520 4,566 -1 1 Japan 1,360 1,425 -5 11 International 5,520 5,324 4 ##### 10 CER: Constant exchange rates (a
Slide 37: HY 2026: Pharmaceuticals core operating profit
HY 2026: Pharmaceuticals core operating profit Core operating profit growing ahead of sales with +10%, driven by effective cost management 2026 2026 vs. 2025 CHFm Abs. CERm CER growth Sales 23,629 +1,453 6% Other revenue 965 +168 20% Cost of sales -4,231 -217 5% R&D -4,895 -40 Includes shift of CHF
Slide 38: HY 2026: Diversified set of key growth drivers
HY 2026: Diversified set of key growth drivers Xolair remaining top growth driver, closely followed by Ocrevus and Hematology franchise Xolair 27% Hemlibra 11% Ocrevus 7% Phesgo 18% Vabysmo 8% Evrysdi 17% Polivy 20% Tecentriq 6% Columvi 70% Itovebi 212% Elevidys 62% Lunsumio 130% Alecensa 6% Enspryn
Slide 39: Oncology growth driven by Phesgo and Tecentriq
Oncology/Hematology Oncology growth driven by Phesgo and Tecentriq Giredestrant: lidERA PDUFA set for 30th Nov; positive Ph III for divarasib in 2L+ KRAS G12C+ NSCLC Q2 update Itovebi ▪ Phesgo: Global conversion rate at 54%* CHF 104m / +74% Others CHF 279m / -9% ▪ Perjeta: Conversion to Phesgo ongoi
Slide 40: Divarasib in 2L+ NSCLC: Superiority in PFS and OS vs. SoC
Oncology/Hematology Divarasib in 2L+ NSCLC: Superiority in PFS and OS vs. SoC Potentially best-in-class KRAS G12C inhibitor; strong divarasib activity in 1L NSCLC in combination with pembro Ph II KRASCENDO 170 efficacy1 Roche RAS-targeted pipeline PD-L1 Positive Cohort, 400mg (N=59)* Molecule Indica
Slide 41: Polivy expanding strong global position in 1L DLBCL
Oncology/Hematology Polivy expanding strong global position in 1L DLBCL (IPI 0-5) Lunsumio in 2L+ DLBCL (SUNMO) with US PDUFA set for 9th Feb Q2 update Lunsumio Columvi CHF 100m / +130% ▪ Hemlibra: Continued global growth; increasing adoption in non- CHF 196m / +70% inhibitor patients PiaSky MabTher
Slide 42: Bexobrutideg: Potential BIC BTK-targeted therapy
Oncology/Hematology Bexobrutideg: Potential BIC BTK-targeted therapy Broad development program in Hematology; ongoing expansion to Neurology and Immunology indications Bexobrutideg (BTK degrader) Development program TA Indication Ph I Ph I Ph II Ph II Ph III Ph III Status 3L+ CLL DAYBreak CLL-201 On
Slide 43: Ocrevus: Global growth driven by SC
Neurology Ocrevus: Global growth driven by SC Ocrevus Zunovo is the fastest growing aCD20 MS treatment in the US Q2 update Elevidys Others ▪ Ocrevus: ~44,000 patients on Ocrevus SC globally with CHF 180m / +62% significant momentum vs. Q1 CHF 157m / -21% Enspryng CHF 195m / +22% ▪ US: ~60% of SC vol
Slide 44: Xolair driving overall Immunology growth
Immunology Xolair driving overall Immunology growth Gazyva: US & EU filing for MN achieved with PDUFA set for 15th Nov; US PDUFA in INS set for 27th Sep Q2 update ▪ Xolair: Growth driven by food allergy Others CHF 402m / -5% Actemra ▪ Food allergy: >130,000 patients treated since launch CHF 1,074m /
Slide 45: Gazyva: Potential to become first approved treatment for MN
Immunology Gazyva: Potential to become first approved treatment for MN Gazyva demonstrated superiority over tacrolimus in CR at week 104; all Gazyva indications filed in US & EU Ph III (MAJESTY) in MN results1,2 Development program Primary endpoint: CR3 (UPCR ≤0.3 g/g and stable eGFR (≥85% of baseli
Slide 46: Vabysmo with continued global market share expansion
Ophthalmology Vabysmo with continued global market share expansion Enspryng in TED US filing and priority review achieved with PDUFA set for 15th Oct Q2 update Susvimo Others ▪ Vabysmo: Continued global growth and market share gains CHF 9m / +109% CHF 39m / -44% ▪ US: >60% of patient starts are naïv
Slide 47: Vabysmo: Expecting continued global market share gains
Ophthalmology Vabysmo: Expecting continued global market share gains Strong, consistent clinical and real-world data on anatomic outcomes and durability across indications ASRS PAT survey: Anatomic outcomes and durability in AMD, DME & RVO1 Global growth outlook Q: Which IVT injection delivers the b
Slide 48: CVRM pipeline progressing
Cardiovascular, Renal & Metabolism CVRM pipeline progressing Ph II data for enicepatide and petrelintide shared at ADA; pipeline progressing towards late-stage Clinical development Q2 update ▪ Enicepatide: Ph II (103) data in obesity presented at ADA Asset Indication Ph I Ph II Ph III ▪ Petrelintide
Slide 49: Enicepatide: Potential for BIC weight loss
Cardiovascular, Renal & Metabolism Enicepatide: Potential for BIC weight loss Broad Ph III development program in obesity, T2D and CVOT with additional trials under evaluation Ph II (103) results in overweight/obesity1 Weight loss (efficacy estimand) Weight reduction thresholds (at 48 weeks) Placebo
Slide 50: 2026: Key newsflow outlook
2026: Key newsflow outlook* Giredestrant + everolimus (post CDKi ER+/HER2- mBC) filed in US; 5 FDA priority reviews achieved Compound Indication Milestone giredestrant adjuvant ER+/HER2- early BC US/EU filing (US) giredestrant + everolimus post CDKi ER+/HER2- mBC EU filing/US approval Gazyva SLE US/
Slide 51: Diagnostics Division
Diagnostics Division Matt Sause CEO Roche Diagnostics
Slide 52: HY 2026: Diagnostics sales
HY 2026: Diagnostics sales Diagnostics growing at +3%, impacted by China healthcare pricing reforms HY 2026 HY 2025 Change in % CHFm CHFm CHF CER Diagnostics Division 6,735 6,959 -3 3 Core Lab 3,756 3,839 -2 4 Molecular Lab 1,196 1,250 -4 3 Near Patient Care 909 1,018 -11 -5 Pathology Lab 874 852 3
Slide 53: HY 2026: Diagnostics highlights
HY 2026: Diagnostics highlights Diagnostics growing at +3%, impacted by China healthcare pricing reforms CHFbn YoY CER growth ▪ Immunodiagnostics (+4%) Core Lab +4% ▪ Clinical chemistry (+7%) Molecular Lab +3% ▪ Transplant (+18%) Near Patient ▪ BGM (+3%) -5% ▪ Liat POC MDx (-20%) Care EMEA North Ame
Slide 54: HY 2026: Diagnostics regional sales
HY 2026: Diagnostics regional sales North America +8% EMEA ~33% of divisional sales +3% ~37% of divisional sales Asia Pacific Latin America -5% +10% ~22% of divisional sales ~8% of divisional sales Growth rates at constant exchange rates (avg. full year 2025); EMEA: Europe, Middle East and Africa 54
Slide 55: HY 2026: Diagnostics core operating profit
HY 2026: Diagnostics core operating profit Core operating profit higher by +6%, driven by higher sales and other revenue 2026 2026 vs. 2025 CHFm Abs. CERm CER growth Sales 6,735 +228 3% Other revenue 123 +90 256% Cost of sales -3,442 -173 5% R&D -870 -27 Includes shift of CHF ~24m 3% (CER) to Corpor
Slide 56: AXELIOS 1 Sequencing platform launch
AXELIOS 1 Sequencing platform launch AXELIOS 1 delivers world-record speed, high accuracy, and multi-modal flexibility Performance1 Key partners SBX-duplex (SBX-D) output ≥ 1.8 Tb (concordant duplex bases per 4 hr run) SBX-D Mean insert length2 ~ 230 to 260 bp Accuracy3 ~ Q38 (concordant duplex base
Slide 57: PathAI acquisition
PathAI acquistion1 Expanding our pathology portfolio with the best-in-class digital pathology solution Roche Diagnostics oncology ecosystem2 PathAI overview ▪ PathAI is an AI-powered precision pathology company Early Precise Therapy Disease Detection Diagnosis Selection Monitoring ▪ Its core offerin
Slide 58: Elecsys pTau217
Elecsys® pTau217 First blood-based biomarker to rule in and rule out Alzheimer’s pathology in primary care Elecsys® pTau217 Market needs and opportunity ▪ Alzheimer's is the leading cause of dementia, a condition projected to affect 80m people by 20301 100% ▪ Diagnosis takes three years after sympto
Slide 59: Elecsys IGRA TB
Elecsys® IGRA TB Entering the attractive latent TB segment and strengthening Roche's Infectious Disease offering 46TH ANNUAL CONGRESS Elecsys® IGRA TB Market needs and opportunity ▪ ~25% of the global population may have been infected with the bacteria that cause TB7 ▪ Expanding access to diagnostic
Slide 60: Diagnostics key launches 2026
Diagnostics key launches 2026 Area Product Description Market Status Molecular Novel high-throughput solution for ultra-rapid, scalable, and flexible sequencing powered by Sequencing by Systems Lab AXELIOS 1 Sequencing Solution Expansion (SBX) technology Global Non-invasive blood-based biomarker to
Slide 61: IR events in 2026
IR events in 2026 Additional events driven by readouts Neurology Update Diagnostics Day Oncology Update CVRM Update Pharma Day 22 Apr 12 May 2 Jun 8 Jun 28 Sep ▪ MS franchise update at ▪ Group and Diagnostics ▪ Oncology franchise ▪ Obesity franchise update ▪ Update on Pharma AAN division strategy up
Slide 62: Doing now what patients need next
Doing now what patients need next
Slide 63: Appendix: Roche Group development pipeline
Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information
Slide 64: Changes to the development pipeline
Changes to the development pipeline Q2 2026 update New to phase I New to phase II New to phase III New to registration 4 NMEs: 3 NMEs: 3 NMEs: 2 AIs: RG6697 NME - DME RG6596 HER2 TKI (ZN-1041) – 2L+ HER2+ mBC RG6512 zemocimig (NXT007) – hemophilia A RG7159 Gazyva - membranous nephropathy RG6852 NME
Slide 65: Roche Group development pipeline
Roche Group development pipeline Phase I (37 NMEs + 6 AIs) Phase II (12 NMEs + 6 AIs) RG6026 Columvi monotherapy + combos heme tumors Muco-obstructive RG6114 Itovebi + enzalutamide CRPC RG6421 TMEM16A potentiator RG6171 giredestrant monotherapy + combos solid tumors respiratory disease RG6114 Itoveb
Slide 66: Roche Group development pipeline
Roche Group development pipeline Phase III (14 NMEs + 21 AIs) Registration US & EU (2 NMEs + 7 AI) RG3502 Kadcyla + T HER-2+ eBC high-risk RG6149 astegolimab COPD giredestrant + post-CDK4/6 ER+/HER2- BC RG6013 Hemlibra Type 3 VWD RG62992 sefaxersen (ASO factor B) IgA nephropathy RG6171 everolimus† C
Slide 67: Expected regulatory submissions
Expected regulatory submissions* New Molecular Entities: Lead and additional indications New Molecular Entity (NME) Cardiovascular, Renal & Metabolism Additional Indication (AI) Neurology Oncology / Hematology Ophthalmology Immunology Other *Filing timelines reflect the anticipated filing of a poten
Slide 68: Expected regulatory submissions
Expected regulatory submissions* Marketed products: Additional indications New Molecular Entity (NME) Cardiovascular, Renal & Metabolism Additional Indication (AI) Neurology Oncology / Hematology Ophthalmology Immunology Other *Filing timelines reflect the anticipated filing of a potential indicatio
Slide 69: Major pending approvals 2026
Major pending approvals 2026 US EU China Japan-Chugai giredestrant + everolimus Tecentriq giredestrant Tecentriq RG6171 post-CDK4/6 ER+/HER2- BC RG7446 stage III dMMR/MSI-H colon cancer RG6171 ER+ BC adj RG7446 ctDNA+ high-risk MIBC Filed December 2025 Filed July 2026 Filed April 2026 Filed January
Slide 70: Major granted approvals 2026
Major granted approvals 2026 US EU China Japan-Chugai Tecentriq Polivy + chemo Lunsumio + Polivy RG7446 ctDNA+ high-risk MIBC RG7596 r/r DLBCL RG7828 r/r large B-cell lymphoma May 2026 March 2026 March 2026 Alecensa RG7853 ALK+ solid tumors May 2026 Avastin RG435 neurofibromatosis Type 2 June 2026 N
Slide 71: Marketed products development programmes
Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information
Slide 72: Marketed products development programmes
Marketed products development programmes Oncology / Hematology Neurology Immunology Ophthalmology CVRM RG7853 Alecensa RG6356 Elevidys RG7159 Gazyva RG6168 Enspryng RG6114 Itovebi RG6168 Enspryng RG7828 Lunsumio RG6321 Susvimo RG3502 Kadcyla RG7916 Evrysdi RG7716 Vabysmo RG7446 Tecentriq RG6026 Colu
Slide 73: Alecensa
Alecensa (alectinib, RG7853) CNS-active inhibitor of anaplastic lymphoma kinase (ALK) Indication Locally advanced, unresectable, stage III NSCLC Phase III Phase/study HORIZON-01 # of patients N=70 ▪ ARM A: Alecensa 600mg BID Oncology/Hematology ▪ ARM B: durvalumab 1500 Q4W Design ▪ Progression-free
Slide 74: Itovebi
Itovebi (inavolisib, RG6114, GDC-0077) A potent, orally available, and selective PI3Kα inhibitor Indication PIK3CA-mutant HR-positive metastatic breast cancer post CDKi HR-positive PIK3CA-mutant breast cancer Phase III Phase III Phase/study INAVO120 INAVO121 # of patients N=320 N=400 ▪ ARM A: Itoveb
Slide 75: Itovebi
Itovebi (inavolisib, RG6114, GDC-0077) A potent, orally available, and selective PI3Kα inhibitor Indication 1L HER2-positive PIK3CA-mutant metastatic breast cancer 1L endocrine-sensitive PIK3CA-mutant HR+, HER2-, adv. breast cancer Phase III Phase III Phase/study INAVO122 INAVO123 # of patients N=23
Slide 76: Itovebi
Itovebi (inavolisib, RG6114, GDC-0077) A potent, orally available, and selective PI3Kα inhibitor Indication 1L HR-positive 1L HR+ Chr8P-loss PIK3CA-wildtype metastatic breast cancer Phase/study Phase II # of patients N=80 ▪ ARM A: Itovebi + ribociclib + fulvestrant Oncology/Hematology ▪ ARM B: Place
Slide 77: Itovebi
Itovebi (inavolisib, RG6114, GDC-0077) A potent, orally available, and selective PI3Kα inhibitor Indication post-ARPI metastatic prostate cancer (mCRPC) Phase II Phase/study InavoPC # of patients N=100 ▪ ARM A: Itovebi + enzalutamide Oncology/Hematology ▪ ARM B: ARPi switch (enzalutamide or abirater
Slide 78: Kadcyla
Kadcyla (trastuzumab emtansine, RG3502) First ADC for HER2-positive breast cancer HER2-positive early breast cancer (BC) Indication high-risk patients Phase III Phase/study ASTEFANIA # of patients N=1150 ▪ ARM A: Kadcyla + Tecentriq Oncology/Hematology Design ▪ ARM B: Kadcyla + placebo ▪ Invasive di
Slide 79: Tecentriq
Tecentriq (atezolizumab, RG7446) Anti-PD-L1 cancer immunotherapy – lung cancer Indication 1L maintenance extensive-stage SCLC Phase III Phase/study IMforte1 # of patients N=450 Oncology/Hematology ▪ ARM A: Platinum-etoposide + Tecentriq followed by maintenance Tecentriq + lurbinectedin Design ▪ ARM
Slide 80: Tecentriq
Tecentriq (atezolizumab, RG7446) Anti-PD-L1 cancer immunotherapy – urothelial carcinoma ctDNA+, high-risk muscle-invasive Indication bladder cancer (MIBC) Phase III Phase/study IMvigor011 # of patients N=240 ARM A: Tecentriq monotherapy Oncology/Hematology ▪ ▪ ARM B: Placebo Design ▪ Disease-free su
Slide 81: Tecentriq
Tecentriq (atezolizumab, RG7446) Anti-PD-L1 cancer immunotherapy – colon cancer Indication Stage III dMMR-deficient or MSI-H colon cancer Phase III Phase/study ATOMIC # of patients N=700 ARM A: Tecentriq + mFOLFOX6 (24 weeks) followed by Tecentriq up to 1yr from start of induction Oncology/Hematolog
Slide 82: Columvi
Columvi (glofitamab, RG6026) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication Relapsed or refractory Non-Hodgkin’s lymphoma (NHL) Phase/study Phase I Phase I # of patients N=700 N=18-36 Cohort 1: Single-agent dose escalation study Columvi SC ▪ Initial dose escalatio
Slide 83: Columvi
Columvi (glofitamab, RG6026) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication 2L+ SCT-ineligible DLBCL Phase/study Phase Ib # of patients N=112 ▪ ARM A: Columvi IV + CELMoD (CC-220 and CC-99282) Oncology/Hematology ▪ ARM B: Lunsumio SC + CELMoD (CC-220 and CC-99282)
Slide 84: Columvi
Columvi (glofitamab, RG6026) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication 2L+ SCT-ineligible DLBCL 1L DLBCL fit (IPI 2-5) Phase III Phase III Phase/study STARGLO SKYGLO # of patients N=270 N=1130 ▪ ARM A: Columvi + gemcitabine and oxaliplatin, followed by up to
Slide 85: Columvi
Columvi (glofitamab, RG6026) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication Relapsed or refractory mantle cell lymphoma (MCL) Phase III Phase/study GLOBRYTE # of patients N=182 ▪ ARM A: Columvi monotherapy Oncology/Hematology ▪ ARM B: Bendamustine + rituximab or r
Slide 86: Lunsumio
Lunsumio (mosunetuzumab, RG7828) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication 2L+ FL Phase III Phase/study CELESTIMO # of patients N=474 ▪ ARM A: Lunsumio + lenalidomide Oncology/Hematology ▪ ARM B: Rituximab + lenalidomide Design ▪ Progression-free survival Pri
Slide 87: Lunsumio
Lunsumio (mosunetuzumab, RG7828) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication 2L+ SCT ineligible DLBCL Relapsed or refractory LBCL & MCL Phase III Phase/study Phase Ib/II SUNMO # of patients N=222 N=235 ▪ ARM A: Lunsumio + Polivy Dose escalation of Lunsumio + Po
Slide 88: Polivy
Polivy (polatuzumab vedotin, RG7596) ADC targeting CD79b to treat B cell malignancies Indication 1L DLBCL Phase III Phase/study POLARIX # of patients N=879 Oncology/Hematology ▪ ARM A: Polivy + R-CHP ▪ ARM B: R-CHOP Design ▪ Progression-free survival Primary endpoint ▪ Data presented at ASH 2021 and
Slide 89: Hemlibra
Hemlibra (emicizumab, RG6013) Factor VIII mimetic for treatment of hemophilia A Indication Type 3 Von Willebrand disease (VWD) Phase III Phase/study WILL-EMI # of patients N=66 Open-label in participants aged 2 years and above diagnosed with Type 3 von Willebrand disease (VWD) on prior SOC on demand
Slide 90: PiaSky
PiaSky (crovalimab, RG6107, SKY59) A humanized monoclonal antibody against complement C5 Atypical hemolytic uremic syndrome (aHUS) Atypical hemolytic uremic syndrome (aHUS) Indication - adults - paediatric Phase III Phase III Phase/study COMMUTE-a COMMUTE-p # of patients N=90 N=35 Single-arm study o
Slide 91: Elevidys
Elevidys (delandistrogene moxeparvovec, RG6356, SRP-9001) rAAVrh74.MHCK7.Micro-dystrophin gene therapy Indication Duchenne muscular dystrophy (DMD) Phase II Phase/study ENVOL # of patients N=13 Neurology Open label single arm study in 2 to <4 year old DMD boys who will receive a single intravenous (
Slide 92: Enspryng
Enspryng (satralizumab, RG6168, SA237) Anti-IL-6 receptor humanized monoclonal antibody Indication Myelin oligodendrocyte glycoprotein antibody disease (MOGAD) Autoimmune encephalitis (AIE) Phase III Phase III Phase/study METEOROID CIELO # of patients N=152 N=152 ▪ ARM A: Enspryng at weeks 0, 2, 4 (
Slide 93: Evrysdi
Evrysdi (risdiplam, RG7916) Oral SMN2 splicing modifier Indication Spinal muscular atrophy (SMA) Phase II Phase II Phase/study RAINBOWFISH JEWELFISH # of patients N=25 N=174 ▪ Infants aged from birth to 6 weeks who have been genetically ▪ Adult and pediatric patients with previously treated SMA type
Slide 94: Gazyva
Gazyva (obinutuzumab, RG7159) Humanized anti-CD20 monoclonal antibody; immunology development program Indication Lupus nephritis Childhood onset idiopathic nephrotic syndrome* Phase III Phase III Phase/study REGENCY INShore # of patients N=252 N=80 ▪ ARM A: Gazyva 1000mg IV (6 doses through Week 52)
Slide 95: Gazyva
Gazyva (obinutuzumab, RG7159) Humanized anti-CD20 monoclonal antibody; immunology development program Indication Systemic lupus erythematosus (SLE) Membranous nephropathy Phase III Phase III Phase/study ALLEGORY MAJESTY # of patients N=300 N=140 ▪ ARM A: Gazyva 1000mg IV on Day 1 and Weeks 2, 24 and
Slide 96: Lunsumio
Lunsumio (mosunetuzumab, RG7828, CD20 x CD3) Bispecific anti-CD20/CD3 antibody engaging T and B cells simultaneously Indication Systemic lupus erythematosus (SLE) Phase II Phase/study SOLUNA # of patients N=30 ▪ Single arm Lunsumio SC Immunology Design ▪ Proportion of participants who have achieved
Slide 97: Enspryng
Enspryng (satralizumab, RG6168, SA237) Anti-IL-6 receptor humanized monoclonal antibody Indication Thyroid eye disease Phase III Phase III Phase/study SatraGO-1 SatraGO-2 # of patients N=120 N=120 ▪ ARM A: Enspryng at weeks 0, 2, 4 (loading doses) and maintenance doses ▪ ARM A: Enspryng at weeks 0,
Slide 98: Susvimo
Susvimo (PDS, RG6321) First eye implant to achieve sustained delivery of a biologic medicine Indication Wet age-related macular degeneration (wAMD) Phase III Phase II+III extension Phase IIIb Phase/study Archway Portal Velodrome # of patients N=418 N=1,000 N=442 ▪ ARM A: PDS 100mg/mL Q24W ▪ Ex-LADDE
Slide 99: Susvimo
Susvimo (PDS, RG6321) First eye implant to achieve sustained delivery of a biologic medicine Diabetic retinopathy (DR) without Indication Diabetic macular edema (DME) center-involved diabetic macular edema (DME) Phase III Phase III Phase/study Pagoda Pavilion # of patients N=634 N=174 ▪ ARM A: Intra
Slide 100: Vabysmo
Vabysmo (faricimab, RG7716) Bispecific antibody for the eye which targets and inhibits two signaling pathways (Ang-2 and VEGF-A) Indication Myopic choroidal neovascularization (CNV) Phase III Phase/study POYANG # of patients n=280 Ophthalmology ▪ ARM A: Vabysmo 6.0 mg Q4W PRN ▪ ARM B: Ranibizumab 0.
Slide 101: Roche Pharma global development programmes
Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information
Slide 102: Roche Pharma global development programmes
Roche Pharma global development programmes Oncology / Hematology Neurology Immunology Ophthalmology CVRM RG6330 Divarasib RG7845 Fenebrutinib RG6299 Sefaxersen RG6179 Vamikibart RG6640 Enicepatide (CT-388) RG6171 Giredestrant RG7935 Prasinezumab RG6631 Afimkibart RG6652 CT-996 RG6596 HER2 TKI RG6042
Slide 103: Divarasib
Divarasib (KRAS G12C inhibitor, RG6330, GDC-6036) A potent, orally available, and selective inhibitor of the KRAS G12C mutant protein Indication 1L NSCLC 2L NSCLC 1L NSCLC Phase Ib/II Phase III Phase III Phase/study KRASCENDO 170 KRASCENDO 1 KRASCENDO 2 # of patients N=320 N=320 N=600 ▪ Cohort A: Co
Slide 104: Giredestrant
Giredestrant (SERD (3), RG6171, GDC-9545) A selective estrogen receptor degrader or downregulator ET resistant ER+/HER2-negative breast cancer Indication Adjuvant ER-positive breast cancer (BC) 1L ER-positive metastatic breast cancer (mBC) (BC) Phase III Phase III Phase III Phase/study lidERA Breast
Slide 105: Giredestrant
Giredestrant (SERD (3), RG6171, GDC-9545) A selective estrogen receptor degrader or downregulator Indication post-CDK4/6 ER-positive/HER2-negative breast cancer (BC) 1L ER-positive/HER2-positive breast cancer (BC) Phase III Phase III Phase/study evERA heredERA # of patients N=373 N=812 Oncology/Hema
Slide 106: HER2 TKI (ZN-1041)
HER 2 TKI (ZN-1041, RG6596) Oral blood-brain barrier penetrant HER2 TKI Indication 2L+ HER2+ mBC Phase II/III Phase/study BREnnA # of patients N=650 Oncology/Hematology ▪ ARM A: ZN-1041 dose 1 + trastuzumab + capecitabine ▪ ARM B: ZN-1041 dose 2 + trastuzumab + capecitabine Design ▪ ARM C: tucatinib
Slide 107: Cevostamab
Cevostamab (RG6919) Bispecific anti-FcRH5/CD3 antibody Indication 2-4L relapsed/refractory multiple myeloma Phase III Phase/study CEVOLUTION # of patients N=380 Oncology/Hematology ▪ ARM A: Cevostamab + Pd ▪ ARM B: SoC (DPd, PVd, EPd) Design ▪ MRD-neg CR at 9 mo Primary endpoint ▪ PFS IRC-assessed ▪
Slide 108: Zemocimig (NXT007)
Zemocimig (NXT007, RG6512) Bispecific antibody which targets Factor IXa and Factor X Indication Hemophilia A Phase I/II Phase/study Phase III (ZEBRHA 1) Phase III (ZEBRHA 2) (multiple-ascending dose) # of patients N=40 N=126 N=360 Oncology/Hematology ▪ Two loading doses of NXT007 SC ▪ H2H vs Factor
Slide 109: Dirloctocogene Samoparvovec
Dirloctocogene Samoparvovec (SPK-8011QQ; RG6797) Gene therapy for Hemophilia A Indication Moderately severe to severe Hemophilia A (>18yrs) Phase/study Phase IIb # of patients N=5 Oncology/Hematology ▪ Participants will receive an IV infusion of dirloctocogene samoparvovec on day 1 Design ▪ Safety P
Slide 110: Fenebrutinib
Fenebrutinib (RG7845, GCD-0853) Highly selective and reversible (noncovalent) bruton tyrosine kinase Indication Relapsing multiple sclerosis (RMS) Phase III Phase III Phase II (Biomarker study) Phase/study FENhance 1 FENhance 2 FENopta # of patients N=746 N=751 N=109 ARM A: Fenebrutinib twice daily
Slide 111: Fenebrutinib
Fenebrutinib (RG7845, GCD-0853) Highly selective and reversible (noncovalent) bruton tyrosine kinase Indication Primary progressive multiple sclerosis (PPMS) Phase III Phase/study FENtrepid # of patients N=985 Neurology ▪ ARM A: Fenebrutinib twice daily oral ▪ ARM B: Ocrevus 2x300mg IV Q24W Design ▪
Slide 112: Prasinezumab
Prasinezumab (anti-αSynuclein; RG7935) Anti-alpha-synuclein antibody under investigation for Parkinson’s disease Indication Early-stage Parkinson's disease PASADENA PADOVA PARAISO Phase/study Phase II Phase IIb Phase III # of patients 316 586 N=900 ▪ PART 1: ▪ ARM A: Prasinezumab IV Q4W ▪ ARM A: Pra
Slide 113: Trontinemab
Trontinemab (BS-anti-Aβ mAb, RG6102) A novel BrainshuttleTM bispecific 2+1 monoclonal antibody targeting Aβ Prodromal or mild to moderate Alzheimer's Indication Early Alzheimer's Disease Disease Phase III Phase III Phase/study Phase I/II TRONTIER 1 TRONTIER 2 # of patients N=210 N=800 N=800 Neurolog
Slide 114: Sefaxersen
Sefaxersen (ASO factor B, RG6299) Antisense oligonucleotide that targets factor B Indication IgA nephropathy (IgAN) Phase III Phase/study IMAGINATION # of patients N=428 ▪ ARM A: Sefaxersen SC at week 1, 3, 5 following Q4W dosing for 104 weeks ▪ ARM B: Placebo Immunology Design ▪ Change in UPCR at w
Slide 115: Afimkibart
Afimkibart (anti-TL1A, RG6631) A monoclonal antibody targeting TL1A, blocking TH1 and TH17 pathways Indication Moderate to severe ulcerative colitis Moderate to severe ulcerative colitis Phase III Phase III Phase/study AMETRINE-1 AMETRINE-2 # of patients N=400 N=350 ▪ ARM A: Afimkibart IV induction
Slide 116: Afimkibart
Afimkibart (anti-TL1A, RG6631) A monoclonal antibody targeting TL1A, blocking TH1 and TH17 pathways Indication Moderate to severe Crohn's Disease Phase III Phase III Phase/study SIBERITE-1 SIBERITE-2 # of patients N=600 N=425 ▪ Treat-through design with no re-randomization after induction ▪ Inductio
Slide 117: Afimkibart
Afimkibart (anti-TL1A, RG6631) A monoclonal antibody targeting TL1A, blocking TH1 and TH17 pathways Metabolic Dysfunction-associated Indication Atopic dermatitis Rheumatoid Arthritis (RA) Steatohepatitis (MASH) Phase II Phase Ib Phase IIb Phase/study VELARITE FIBROLITE dRAvite # of patients N=160 N=
Slide 118: Vamikibart
Vamikibart (anti-IL-6, RG6179) A monoclonal antibody that potently binds interleukin-6 (IL-6) cytokine Indication Uveitic macular edema (UME) Phase III Phase III Phase/study MEERKAT SANDCAT # of patients N=225 N=225 ARM A: Vamikibart low-dose Q4W to week 12, followed by PRN ARM A: Vamikibart low-dos
Slide 119: Enicepatide
Enicepatide (CT-388, RG6640) Once-weekly subcutaneous injectable dual GLP-1/GIP receptor agonist Indication Overweight/obesity without type 2 diabetes Phase/study Phase II Phase III Enith 1 # of patients N=450 N=2000 ▪ enicepatide (low/med/high dose) vs. placebo ▪ Arm 1: Placebo Arm 2: CT-388 dosing
Slide 120: Enicepatide
Enicepatide (CT-388, RG6640) Once-weekly subcutaneous injectable dual GLP-1/GIP receptor agonist Indication Overweight/obesity with type 2 diabetes Phase/study Phase II Phase III Enith 2 # of patients N=360 N=1600 ▪ enicepatide (low/med/high dose) vs. placebo ▪ Arm 1: Placebo Arm 2: Enicepatide dosi
Slide 121: CT-996
CT-996 (GLP-1 RA, RG6652) Once-daily oral small molecule GLP-1 receptor agonist Overweight/obesity with or without type 2 Indication Obesity without type 2 diabetes Glycaemic control trial with T2D participants diabetes Phase/study Phase I Phase II Phase II # of patients N=118 N=340 N=240 Cardiovasc
Slide 122: Emugrobart
Emugrobart (RG6237, GYM 329) Recycling and antigen-sweeping monoclonal anti-latent myostatin antibody Indication Obesity Phase II Phase/study Phase Ib GYMINDA # of patients N=30-36 N=234 ▪ Cohort A (n=15-18): Single dose emugrobart 50mg SC ▪ 48w DB Tx period: ▪ Cohort B (n=15-18): Multiple dosing 18
Slide 123: Pegozafermin
Pegozafermin (RG6881) Fibroblast growth factor 21 (FGF21) analog Indication MASH F2-F3 MASH with compensated cirrhosis (F4) Phase III Phase III Phase/study ENLIGHTEN-Fibrosis ENLIGHTEN-Cirrhosis # of patients N=1050 N=762 ▪ ARM A: Placebo ▪ ARM A: Placebo ▪ ARM B: Pegozafermin 30mg QW ▪ ARM B: Pegoz
Slide 124: Roche Pharma research and early development (pRED)
Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information
Slide 125: pRED oncology, neurology development programs
pRED oncology, neurology development programs Molecule Indication Phase # of patients Status CT Identifier Oncology CEA212Pb PRIT (RG6375)1 metastatic Colorectal Cancer (mCRC) I 160 FPI expected Q3 2026 NCT07416552 PanRAS inhibitor (RG6505) solid tumors I 345 FPI Q2 2025 NCT06884618 Neurology ISRCTN
Slide 126: pRED immunology, ophthalmology and CVRM development programs
pRED immunology, ophthalmology and CVRM development programs Molecule Indication Phase # of patients Status CT Identifier Immunology NME (RG6498) IBD I FPI Q1 2026 anti-TSLP:IL33 (RG6981)1 COPD/Asthma I 120 FPI Q1 2026 ISRCTN22936350 Ophthalmology VEGF x IL6 DutaFab FPI Q4 2022 NCT06847854 DME I 176
Slide 127: Genentech research and early development (gRED)
Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information
Slide 128: gRED oncology development programs
gRED oncology development programs Molecule Indication Phase # of patients Status CT Identifier Oncology autogene cevumeran NCT05968326 (Individualized Neoantigen-Specific adjuvant PDAC II 260 FPI Q4 2023 (IMcode003) Therapy (iNeST); RG6180)1 CDK4/2i (RG6794, GDC-4198) HR+ HER2- Breast cancer Ib/II
Slide 129: gRED neurology, immunology, ophthalmology development programs
gRED neurology, immunology, ophthalmology development programs Molecule Indication Phase # of patients Status CT Identifier Immunology TMEM16A potentiator (RG6421, muco-obstructive respiratory disease Ic 128 FPI Q4 2024 NCT06603246 GDC-6988) NCT06979336 p40 x TL1A bispecific (RG6730)1 ulcerative col
Slide 130: Pharma sales appendix
Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information
Slide 131: HY 2026: Pharma Division sales
HY 2026: Pharma Division sales Top 20 products Global US Europe Japan International CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER Ocrevus 3,470 7 2,300 2 758 10 - - 412 30 Hemlibra 2,492 11 1,313 9 502 4 171 9 506 26 Vabysmo 2,059 8 1,333 1 386 5 75 26 265 65 Tecentriq 1,704 6 815 9 410 -3
Slide 132: HY 2026: Pharma Division sales
HY 2026: Pharma Division sales Products launched since 2015 Global US Europe Japan International CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER Cotellic 23 2 11 7 5 -9 - - 7 2 Alecensa 795 6 261 4 126 -4 93 8 315 13 Tecentriq 1,704 6 815 9 410 -3 146 -2 333 17 Ocrevus 3,470 7 2,300 2 758 10
Slide 133: HY 2026: Pharma Division sales
HY 2026: Pharma Division sales Product sales Pharmaceuticals Division Global US Europe Japan International CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER Ocrevus 3,470 7 2,300 2 758 10 - - 412 30 Hemlibra 2,492 11 1,313 9 502 4 171 9 506 26 Vabysmo 2,059 8 1,333 1 386 5 75 26 265 65 Tecentri
Slide 134: Pharma Division CER sales growth in %
Pharma Division CER sales growth in % Global top 20 products Q1/25 Q2/25 Q3/25 5 Q4/25 Q1/26 Q2/26 Ocrevus 6 10 6 16 6 7 Hemlibra 11 22 4 8 13 9 Vabysmo 18 19 4 7 13 3 Tecentriq 0 -1 4 8 4 9 Xolair 26 41 34 26 26 28 Perjeta -10 -14 -14 -13 -11 -3 Phesgo 52 57 51 34 27 9 Actemra / RoActemra -1 8 -2 -
Slide 135: Pharma Division CER sales growth in %
Pharma Division CER sales growth in % Top 20 products by region US Europe Japan International Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Ocrevus 1 17 3 2 12 14 9 11 - - - - 35 11 24 37 Hemlibra -1 6 15 4 14 12 5 3 11 5 18 3 9 18 14 39 Vabysmo -4 -1 4 -2 9 13 0 10 17 15 39 16 111 118 126 24 Tece
Slide 136: HY 2026: CER sales growth (%)
HY 2026: CER sales growth (%) Quarterly development 2025 vs. 2024 2026 vs. 2025 Q1 Q2 Q3 Q4 Q1 Q2 Pharma Division 8 11 7 9 7 6 United States 6 13 5 9 5 7 Europe 5 5 5 7 -1 3 Japan 3 7 6 4 14 9 International 18 11 11 16 16 4 Diagnostics Division 0 0 2 6 3 4 Roche Group 6 8 6 8 6 5 0 CER: Constant exc
Slide 137: Ocrevus
Ocrevus Global sales CER growth Regional sales CER growth CHFbn +7% 4.0 US +2% 3.5 3.0 Europe +10% 2.5 2.0 1.5 1.0 International +30% 0.5 0.0 HY 2023 HY 2024 HY 2025 HY 2026 HY 2026 sales of CHF 3,470m ▪ US: Moving into earlier lines displacing orals; SC launch ongoing; #1 in US for both dynamic and
Slide 138: Hemlibra
Hemlibra Global sales CER growth Regional sales CER growth CHFbn +11% 3.0 US +9% Europe +4% 2.5 2.0 Japan +9% 1.5 1.0 International +26% 0.5 0.0 HY 2023 HY 2024 HY 2025 HY 2026 HY 2026 sales of CHF 2,492m ▪ US: Continued share gains in non-inhibitor patients ▪ EU: Continued share gains in non-inhibi
Slide 139: Vabysmo
Vabysmo Global sales CER growth Regional sales CER growth CHFbn +8% 2.5 US +1% 2.0 Europe +5% 1.5 1.0 Japan +26% International +65% 0.5 0.0 HY 2023 HY 2024 HY 2025 HY 2026 HY 2026 sales of CHF 2,059m ▪ US: Sales impacted by branded market contraction, continued market share expansion in branded IVT
Slide 140: Tecentriq
Tecentriq Global sales CER growth Regional sales CER growth CHFbn +6% 2.0 US +9% Europe -3% 1.5 Japan -2% 1.0 International +17% 0.5 0.0 HY 2023 HY 2024 HY 2025 HY 2026 HY 2026 sales of CHF 1,704m ▪ US: Growth driven by new indications ▪ EU: Growth impacted by buying patterns in Q1 ▪ International:
Slide 141: Xolair
Xolair Global sales CER growth Regional sales CER growth CHFbn +27% 1.8 1.6 1.4 US +27% 1.2 1.0 0.8 0.6 0.4 0.2 0.0 HY 2023 HY 2024 HY 2025 HY 2026 HY 2026 sales of CHF 1,673m ▪ US: Strong food allergy launch as key growth driver; Strong CSU performance driving additional growth CER: Constant exchan
Slide 142: Perjeta
Perjeta Global sales CER growth Regional sales CER growth CHFbn -7% 2.5 US -11% Europe -14% 2.0 Japan -23% 1.5 1.0 International 0% 0.5 0.0 HY 2023 HY 2024 HY 2025 HY 2026 HY 2026 sales of CHF 1,389m ▪ US: Increasing conversion to Phesgo ▪ EU: Conversion to Phesgo ▪ Japan: Conversion to Phesgo ▪ Int
Slide 143: Phesgo
Phesgo Global sales CER growth Regional sales CER growth CHFbn +18% 1.4 US 0% 1.2 Europe +9% 1.0 0.8 Japan +15% 0.6 0.4 International +47% 0.2 0.0 HY 2023 HY 2024 HY 2025 HY 2026 HY 2026 sales of CHF 1,318m ▪ US: Increasing conversion rates from Perjeta+Herceptin to Phesgo ▪ EU: Strong growth in all
Slide 144: Actemra/RoActemra
Actemra/RoActemra ra / RoActemra Global sales CER growth Regional sales CER growth CHFbn -9% 1.4 US -9% 1.2 Europe -21% 1.0 Japan +8% 0.8 0.6 0.4 International -3% 0.2 0.0 HY 2023 HY 2024 HY 2025 HY 2026 HY 2026 sales of CHF 1,074m ▪ US: Decline due to biosimilars ▪ EU: Decline due to biosimilars ▪
Slide 145: Evrysdi
Evrysdi Global sales CER growth Regional sales CER growth CHFbn +17% 1.2 US +15% Europe +17% 1.0 0.8 Japan -1% 0.6 0.4 International +25% 0.2 0.0 HY 2023 HY 2024 HY 2025 HY 2026 HY 2026 sales of CHF 968m ▪ US: Strong uptake across all patient segments; including treatment-naïve patients ▪ EU: Contin
Slide 146: Kadcyla
Kadcyla Global sales CER growth Regional sales CER growth CHFbn -6% US -14% 1.2 Europe -4% 1.0 0.8 Japan +2% 0.6 0.4 International +3% 0.2 0.0 HY 2023 HY 2024 HY 2025 HY 2026 HY 2026 sales of CHF 916m ▪ US: Impacted by competition in metastatic BC ▪ EU: Share decline in metastatic BC due to competit
Slide 147: Polivy
Polivy Global sales CER growth Regional sales CER growth CHFbn +20% 1.0 US +28% Europe -18% 0.8 Japan +16% 0.6 0.4 International +47% 0.2 0.0 HY 2023 HY 2024 HY 2025 HY 2026 HY 2026 sales of CHF 808m ▪ US: Strong growth following approval in 1L DLBCL ▪ EU: Strong growth following approval in 1L DLBC
Slide 148: Alecensa
Alecensa Global sales CER growth Regional sales CER growth CHFbn +6% 1.0 US +4% Europe -4% 0.8 Japan +8% 0.6 0.4 International +13% 0.2 0.0 HY 2023 HY 2024 HY 2025 HY 2026 HY 2026 sales of CHF 795m ▪ US: Strong position in 1L ALK+ NSCLC is maintained; competitive pressure in 1L ▪ EU: Strong position
Slide 149: MabThera/Rituxan
MabThera/Rituxan Global sales CER growth Regional sales CER growth CHFbn +5% 1.0 US +14% 0.9 0.8 Europe -9% 0.7 Japan -11% 0.6 0.5 0.4 0.3 International -10% 0.2 0.1 0.0 HY 2023 HY 2024 HY 2025 HY 2026 HY 2026 sales of CHF 609m ▪ US: Biosimilar erosion slowing; HY boosted by 2025 base effect ▪ EU: B
Slide 150: TNKase/Activase
TNKase/Activase Global sales CER growth Regional sales CER growth CHFbn +11% 0.7 0.6 0.5 US +11% 0.4 0.3 0.2 International +12% 0.1 0.0 HY 2023 HY 2024 HY 2025 HY 2026 HY 2026 sales of CHF 555m ▪ Spontaneous TNKase use in AIS early time window; Q2 boosted by one-off buying pattern CER: Constant exch
Slide 151: Gazyva
Gazyva Global sales CER growth Regional sales CER growth CHFbn +7% 0.6 US +4% Europe -1% 0.5 0.4 Japan +14% 0.3 0.2 International +21% 0.1 0.0 HY 2023 HY 2024 HY 2025 HY 2026 HY 2026 sales of CHF 489m ▪ US: Increasing competitive pressure in CLL and FL; Ongoing launch in LN ▪ EU: Growth in 1L CLL pa
Slide 152: Herceptin
Herceptin Global sales CER growth Regional sales CER growth CHFbn -12% 1.0 US -14% Europe -7% 0.8 Japan -36% 0.6 0.4 International -14% 0.2 0.0 HY 2023 HY 2024 HY 2025 HY 2026 HY 2026 sales of CHF 462m ▪ US: Biosimilar erosion slowing; Switching of patients with residual disease to Kadcyla; Conversi
Slide 153: Diagnostics sales appendix
Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information
Slide 154: HY 2026: Diagnostics Division CER growth
HY 2026: Diagnostics Division CER growth By Region and Customer Area (vs. 2025) Global EMEA North America Asia-Pacific Latin America CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER Core Lab Core Lab 3,756 4 1,520 6 799 12 1,076 -5 361 11 Molecular Lab 1,196 3 343 5 646 4 159 -6 48 6 Near Pati
Slide 155: HY 2026: Diagnostics Division quarterly sales and CER growth
HY 2026: Diagnostics Division quarterly sales and CER growth1 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 CHFm % CER CHFm % CER CHFm % CER CHFm % CER CHFm % CER Core Lab 1,935 -3 1,849 0 1,926 6 1,798 4 1,958 5 Molecular Lab 616 3 611 5 666 6 571 0 625 6 Near Patient Care 482 0 459 -5 506 -2 465 -5 444 -5 Patholo
Slide 156: HY 2026: Diagnostics Division regional sales
HY 2026: Diagnostics Division regional sales Growth across regions, offset by APAC Sales YTD CHFm / % of total sales Total CHFm = 6,735 (3% at CER) +228 Growth at CER % -86 536 / EMEA +3 +49 8% +181 North America +8 1,522 / 22% of which US +8 2,466 / 37% Asia-Pacific -5 1 of which China -15 +84 2,21
Slide 157: Core Lab
Core Lab 2026 vs. 2025 CER growth CHFbn +4% 4.5 4.0 0% 3.5 +7% 3.0 +4% 2.5 2.0 1.5 1.0 0.5 0.0 HY 2024 HY 2025 HY 2026 Immunodiagnostics Clinical Chemistry Other CER: Constant exchange rates (avg. full year 2025) 157
Slide 158: Molecular Lab
Molecular Lab 2026 vs. 2025 CER growth CHFbn +3% 1.4 +5% 1.2 -52% 1.0 +8% 0.8 +6% 0.6 -8% -3% 0.4 -1% 0.2 +7% 0.0 HY 2024 HY 2025 HY 2026 Infectious Diseases Blood Screening MD Systems Open Molecular Systems Cervical Cancer Sequencing ML Companion Diagnostics Other CER: Constant exchange rates (avg.
Slide 159: Near Patient Care
Near Patient Care 2026 vs. 2025 CER growth CHFbn -5% 1.2 -42% 1.0 -20% 0.8 +3% -3% 0.6 -4% 0.4 -8% 0.2 0.0 HY 2024 HY 2025 HY 2026 Clinical Chem. & Immunodiagn. Hospital Glucose Coagulation & Urinalysis BGM POC MDx Other CER: Constant exchange rates (avg. full year 2025); BGM: Blood Glucose Monitori
Slide 160: Pathology Lab
Pathology Lab 2026 vs. 2025 CER growth CHFbn +11% 1.0 +45% 0.8 +24% +9% 0.6 +7% 0.4 0.2 0.0 HY 2024 HY 2025 HY 2026 Advanced Staining Primary Staining PL Companion Diagnostics Other CER: Constant exchange rates (avg. full year 2025); PL: Pathology Lab 160
Slide 161: Foreign exchange rates information
Roche Group development pipeline Marketed products development programmes Roche Pharma global development programmes Roche Pharma research and early development (pRED) Genentech research and early development (gRED) Pharma sales appendix Diagnostics sales appendix Foreign exchange rates information
Slide 162: Exchange rate impact on sales growth
Exchange rate impact on sales growth Negative impact mainly driven by the USD, JPY, EUR, ARS (LATAM), CNY (APAC) and TRY (Other) -0.4%p -0.7%p CER +5.6% CHF sales growth sales growth -4.6%p 2026 2026 vs. vs. 2025 2025 -0.2%p -0.8%p -1.9% -0.8%p CER EUR APAC USD LATAM JPY Other CHF CER: Constant exch
Slide 163: CHF/USD
CHF/USD Monthly averages 0.95 0.85 -11% -2% 0.75 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2025 2026 Year-to-date averages 0.95 0.85 -13% -9% 0.75 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2025 2026 163
Slide 164: CHF/USD
CHF/USD 0.95 HY 2026 -5% 0.93 0.91 0.89 0.87 0.85 0.83 0.81 0.79 0.77 0.75 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec avg. full year 2025 avg. full year 2026 monthly avg. 2025 monthly avg. 2026 164
Slide 165: CHF/EUR
CHF/EUR Monthly averages 1.00 0.95 0.90 -5% -2% 0.85 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2025 2026 Year-to-date averages 1.00 0.95 0.90 -3% -2% 0.85 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec 2025 2026 165
Slide 166: CHF/EUR
CHF/EUR 0.96 HY 2026 -2% 0.95 0.94 0.93 0.92 0.91 0.90 Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec avg. full year 2025 avg. full year 2026 monthly avg. 2025 monthly avg. 2026 166
Slide 167: Average CHF exchange rates
Average CHF exchange rates HY 2026 HY 2025 HY 2026 vs. HY 2025 USD 0.79 0.86 -9% EUR 0.92 0.94 -2% JPY 0.50 0.58 -14% -18% -15% -12% -9% -6% -3% 0% 167
Slide 168: Exchange rate impact on sales growth
Exchange rate impact on sales growth HY 2026: Negative impact of JPY, USD, CNY, and EUR Development of average exchange rates versus prior year period Q1 HY YTD Sep FY CHF / USD -12.9% -8.9% CHF / EUR -3.0% -2.5% CHF / JPY -15.3% -14.3% CHF / CNY -8.3% -3.6% Difference in CHF / CER -10.6%p -7.5%p gr
Slide 169: Exchange rate impact on sales growth
Exchange rate impact on sales growth HY 2026: Negative impact of JPY, USD and EUR Development of average exchange rates versus prior year period Q1 Q2 Q3 Q4 CHF / USD -12.9% -4.5% CHF / EUR -3.0% -1.9% CHF / JPY -15.3% -13.3% CHF / CNY -8.3% 1.5% Difference in CHF / CER -10.6%p -4.4%p growth 6.0% 5.
Slide 170: Doing now what patients need next
Doing now what patients need next